FDA CRL - ACCORD BIOPHARMA INC

The FDA issued a Complete Response Letter (CRL) to Accord BioPharma, Inc. for its Biologics License Application (BLA 761147). The decision not to approve the application in its current form is primarily due to unresolved manufacturing facility deficiencies. Following recent inspections, the FDA conveyed findings to the drug substance and drug product manufacturing facility, and the company's responses have not yet fully resolved these outstanding items. The FDA requires satisfactory responses to these inspectional observations.

Additionally, the application requires a comprehensive safety update. This includes providing new clinical data, detailed analyses of adverse events, case report forms for subject deaths or study discontinuations due to adverse events, updated exposure information, and a summary of worldwide safety experience. While the proposed proprietary name was conditionally acceptable, it needs to be resubmitted once all application deficiencies are addressed. Comments on prescribing information and carton/container labeling are reserved until the application is otherwise adequate.

Under the regulatory framework governing biologics applications, Accord BioPharma must fully address all deficiencies outlined in this letter. A complete resubmission is required within one year, failing which the application may be considered withdrawn. The company may also request a meeting with the FDA to discuss the necessary steps for approval. Until written approval is granted, the product cannot be legally marketed.